McDonald's Corp vs TransMedics Group Inc — how do they compare? McDonald's Corp trades at $273.98 (market cap $194.00B), while TransMedics Group Inc trades at $89.19 (market cap $3.10B). The key difference: McDonald's Corp is far larger — about 62.6× TransMedics Group Inc's market cap, and McDonald's Corp pays a 2.71% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MCD | TMDX | |
|---|---|---|
Market Cap | $194.00B | $3.10B |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $341.06 | $150.42 |
52-Week Low | $262.80 | $61.99 |
Enterprise Value | $247.77B | $3.49B |
Dividend Yield | 2.71% | — |
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $274.15, down slightly by 0.12% on the day, with technical indicators showing a neutral overall signal. The company demonstrates strong fundamentals with consistent revenue growth, reaching $26.89 billion in 2025, and robust profitability with a 31.72% net income margin. Recent earnings have consistently beaten expectations, and the company has announced a new global growth strategy focused on automation and menu innovation to drive future performance.
The outlook for MCD is positive, supported by strong analyst consensus with a $322.45 price target implying significant upside. Key opportunities include the successful execution of its new growth plan and its defensive qualities in a challenging economy. Primary risks involve inflationary pressures on franchisee margins and intense competition in the quick-service restaurant sector.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →